CYP inhibitor

Haidar, S., P.B. Ehmer, S. Barassin, C. Batzl-Hartmann, and R.W. Hartmann (2003). Effects of novel 17alpha-hydroxylase/C 17,20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J. Steroid Biochem. Mol. Biol. 84, 555-562. 

Ross SA (2015) A multipUcity of targets evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes. Curr MedRes Opin 31 125-135 RovieUo G, Sigala S, Danes R et al (2016) Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors a meta-analysis of published trials. Crit Rev Oncol Hematol 101 12-20 Sankoh AJ, Li H, D Agostino RB Sr (2016) Use of composite endpoints in cUnical trials. Stat Med 35 319-320... 

Hollenberg, P.F. (2002) Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metabolism Reviews, 34 (1-2), 17-35. 

There are several examples of autoimmune hepatitis caused by mechanism-based inhibitors in the field of CYPs hepatitis induced by halothane (CYP2E1) [15,16], by tienilic acid (CYP2C9) [17] and by dihydralazine (CYP1A2) [18,19]. 

Sedatives or anticonvulsants (e.g., carbamazepine, oxcarbazepine, phenobarbital, and pheny-toin, but not valproate) that induce CYPs (see Chapter S) can enhance the metabolism of antipsychotic and many other agents (including anticoagulants and oral contraceptives), sometimes with significant clinical consequences. Conversely, selective serotonin (5-HT) reuptake inhibitors including fluvoxamine, fluoxetine, paroxetine, venlafaxine, sertraline, and nefazodone (see Chapter 17) compete for these enzymes and can elevate circulating levels of neuroleptics. 

---